Akums Drugs and Pharmaceuticals Ltd

Fri 13/11/2026,15:24:54 | NSE : AKUMS

₹741.25-8.65 (-1.15%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 745.00

Previous Close

₹ 749.90

Volume

124951

Mkt Cap ( ₹ Cr)

₹ 11666.83

High

₹ 754.95

Low

₹ 738.75

52 Week High

₹ 838.80

52 Week Low

₹ 409.30

Book Value Per Share

₹ 216.98

Dividend Yield

0.40

Face Value

₹ 2.00

What's Your Call?

Collective community sentiment on Akums Drugs and Pharmaceuticals Ltd

Your Vote -

Buy

76.32%

Hold

13.16%

Sell

10.53%

76.32%

38 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

741.05

14

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

14

Option Chain

Analyzes market sentiment, predicts Akums Drugs and Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Nov 2026, 4:28PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Nov 2026, 5:14PM Intimation of Schedule of the Investors/Analysts Meet
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    5 Nov 2026, 3:04PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Transcript
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    5 Nov 2026, 3:03PM Transcript of the Earning/Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30, 2026
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Nov 2026, 3:39PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Link of Recording
  • Akums Drugs&Pharma. - Copy of Newspaper Publication

    3 Nov 2026, 2:48PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Newspaper Publication
  • Akums Drugs&Pharma. - Monitoring Agency Report

    3 Nov 2026, 2:28PM Final Report of CRISIL Ratings Limited, Monitoring Agency
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    3 Nov 2026, 3:36PM Audio recording of Earning/ Quarterly Conference Call
  • Akums Drugs&Pharma. - Newspaper Publication

    3 Nov 2026, 2:46PM Newspaper Publication
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    3 Nov 2026, 2:24PM Final Report of CRISIL Ratings Limited, Monitoring Agency
  • Akums Drugs&Pharma. - Investor Presentation

    2 Nov 2026, 6:22PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Investor Presentation
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Investor Presentation

    2 Nov 2026, 6:18PM Q2 FY 2026-27 - Investor Presentation
  • Akums Drugs&Pharma. - Press Release

    2 Nov 2026, 6:07PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 02, 2026, titled ""Press Release"".
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    2 Nov 2026, 6:05PM Press Release
  • Akums Drugs&Pharma. - Change in Management

    2 Nov 2026, 5:31PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about change in Management
  • Akums Drugs&Pharma. - Updates

    2 Nov 2026, 5:29PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Unaudited (standalone & consolidated) financial results for the quarter a
  • Akums Drugs&Pharma. - Outcome of Board Meeting

    2 Nov 2026, 5:15PM Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
  • Akums Drugs&Pharma. Q2 net profit up 39.13% at Rs 32.64 cr

    2 Nov 2026, 5:40PM The company reported standalone net profit of Rs 32.64 crore for the quarter ended September 30, 2026 as compared to Rs 23.46 crore in the same period
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Change in Management

    2 Nov 2026, 5:35PM Mr. Sanjay Kumar has been designated as Senior Management Personnel of the Company.
  • Akums Drugs&Pharma. - Unaudited (Standalone & Consolidated) Financial Results For The Quarter And Half Year Ended On 30Th Sep

    2 Nov 2026, 5:27PM Unaudited (standalone & consolidated) financial results for the quarter and half year ended on 30th September, 2026
  • Akums Drugs&Pharma. - Board Meeting Outcome for Outcome Of The Board Meeting

    2 Nov 2026, 5:18PM Outcome of the Board Meeting
  • Akums Drugs&Pharma. - Resignation of Director/KMP/SMP

    31 Oct 2026, 6:46PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Resignation of Director/KMP/SMP
  • Akums Drugs&Pharma. - Change in Management

    31 Oct 2026, 6:41PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about change in Management
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Change in Management

    31 Oct 2026, 6:36PM Cessation of Mr. Sunil Jaiswal as Senior Management Personnel
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    28 Oct 2026, 3:58PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    28 Oct 2026, 3:55PM Intimation of Schedule of the Investors/Analysts Conference Call (group meet) for un-audited financial results of Q2 FY 2026-27
  • Akums Drugs&Pharma. - Board Meeting Intimation for Intimation Of Board Meeting

    28 Oct 2026, 3:41PM Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia,
  • Akums Drugs&Pharma. - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulation

    15 Oct 2026, 4:39PM Demand Notice - National Pharmaceuticals Pricing Authority
  • Akums Drugs&Pharma. - Action(s) taken or orders passed

    15 Oct 2026, 4:31PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed
  • Akums Drugs&Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2026

    12 Oct 2026, 5:50PM As of September 2026, 75.26% is owned by Indian Promoters, 22.01% by Public and 2.73% by Non Promoters-Non Public. <p align=justify> Institutional hol
  • Akums Drugs&Pharma. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    9 Oct 2026, 6:22PM Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
  • Akums Drugs&Pharma. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    9 Oct 2026, 6:15PM Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
  • Akums Drugs&Pharma. - Trading Window

    25 Sep 2026, 4:17PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Tradin
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    23 Sep 2026, 6:12PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    23 Sep 2026, 6:09PM Intimation of Schedule of the Institutional Investors Meets
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    16 Sep 2026, 4:19PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    16 Sep 2026, 4:24PM Intimation of Schedule of Investors/Analysts Meet
  • Akums Drugs&Pharma. - General Updates

    3 Sep 2026, 3:00PM Intimation of ESG Rating
  • Akums Drugs&Pharma. - ESG Rating

    3 Sep 2026, 3:03PM Intimation of ESG Rating
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    25 Aug 2026, 4:43PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    25 Aug 2026, 4:51PM Intimation of Schedule of the Investors/Analysts Meet
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    24 Aug 2026, 3:03PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about an Update on schedule of the Investors/ Analysts Meet to be held on August 25,
  • Akums Drugs&Pharma. - Update On Schedule Of The Investors/Analysts Meet To Be Held On August 25, 2026

    24 Aug 2026, 3:09PM Akums Drugs and Pharmaceuticals Limited has informed the exchange about an update on schedule of the Investors/ Analysts Meet to be held on August 25,
  • Akums Drugs&Pharma. Q1 net profit down 0.07% at Rs 44.84 cr

    22 Aug 2026, 7:50PM The company reported standalone net profit of Rs 44.84 crore for the quarter ended June 30, 2026 as compared to Rs 44.87 crore in the same period last

Key fundamentals

Evaluate the intrinsic value of Akums Drugs and Pharmaceuticals Ltd stock 

Name March-26 March-25 March-24
Assets 2441.119 2309.177 370.164
Liabilities 2441.119 2309.177 370.164
Equity 30.621 30.621 28.613
Gross Profit 97.46 138.499 -126.658
Net Profit 111.64 160.998 -165.451
Cash From Operating Activities -2.147 91.002 247.907
NPM(%) 8.27 12.27 -11.45
Revenue 1348.736 1311.784 1444.119
Expenses 1251.276 1173.285 1570.777
ROE(%) 3.26 4.71 -4.84

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
03 Jul 2026 1 50 0.4 516.95

Peers

Other companies within the same industry or sector that are comparable to Akums Drugs and Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 782.50 -0.82 15.54 422.65 -26.19 0.64
Lotus Eye Hospital and Institute Ltd 103.00 -0.07 468.18 1540.07 0.39 0.00
Vaishali Pharma Ltd 7.11 0.85 22.22 9661.36 15.42 0.00
Astec Lifesciences Ltd 548.80 2.20 0.00 1650.10 -363.14 0.00

Company Info

Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited 2024 -The Company has informed to exchange regarding new product launches.

Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited 2024 -The Company has informed to exchange regarding new product launches.

Parent Organisation

Akums Drugs & Pharmaceuticals Ltd.

Founded

19/04/2004

Managing Director

Mr.Sanjeev Jain

NSE Symbol

AKUMSEQ

FAQ